Open AccessANTITHROMBIN III TREATMENT IMPROVES PARAMETERS OF ACUTE INFLAMMATION IN A HIGHLY HISTOINCOMPATIBLE MODEL OF RAT LUNG ALLOGRAFT REJECTION
Author(s) -
Yoshinori Okada,
Xiao-Jing Zuo,
Alberto M. Marchevsky,
Electra Nicolaidou,
Mieko Toyoda,
Jack M. Matloff,
Stanley C. Jordan
Publication year - 1999
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-199902270-00006
Subject(s) - spleen , medicine , inflammation , edema , lung , sepsis , antithrombin , concanavalin a , immunology , pharmacology , heparin , biology , biochemistry , in vitro
Antithrombin III (AT-III) is an antithrombotic agent with known anti-inflammatory properties that is also known to attenuate acute inflammation, prevent ischemia-reperfusion injury, and disseminated intravascular coagulation (DIC) associated with sepsis and endotoxemia. Here, we examined the ability of AT-III to modify parameters of acute inflammation in a highly histoincompatible model of rat lung allograft rejection (AR).